Australia-based MindBio Therapeutics Corp., an ex-subsidiary to Blackhawk Corp. received ethics approval for a Phase 2 clinical trial assessing the effects of LSD microdoses, paired with meaning-centered psychotherapy, on patients with advanced-stage cancer.

The randomized, double-blind, placebo-controlled study follows positive outcomes from a Phase 1 trial on healthy volunteers including increases in energy, social connectivity, creativity, wellness and happiness as well as tolerance to the LSD microdoses.

CEO Justin Hanka said the clinical data collected so far has exceeded the company’s expectations and …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.